ESTIMATION THE LEVEL OF ADROPIN FOR IRAQI PATIENTS WITH CARDIAC DISEASE AND ATHEROSCLEROSIS AND THE FACTORS AFFECTING ITS LEVEL

Abstract

Adropin is a biomarker for cardiac disease and atherosclerosis. Discovered in 2008, this peptide is involved in controlling the metabolism of carbohydrates and fatty acids. Detailed knowledge of these peptides' mechanisms and the factors that affect their release can provide new diagnostic and treatment of metabolic disorders, including cardiac disease and atherosclerosis. This study aimed to estimate the level of adropin for Iraqi patients with cardiac disease and atherosclerosis and the factors affecting its level and its relationship with the studied variables. This study was conducted on 130 adults, including 90 patients suffering from cardiac disease and atherosclerosis, and 40 uninfected adults were considered a control group. Serum levels of adropin and lipid profile (HDL, LDL, and TC) were estimated . The results of the study showed a significant decrease in the level of adropin (p 0.0001) in the following cases: generally in all patients who affected with cardiac disease and atherosclerosis (4.3 ± 1.5 ng ml) compared with healthy subjects (10.2 ± 2.3 ng mL); in obese patients (3.4 ± 0.7 ng mL) compared to non-obese patients (5.2 ± 1.2 ng mL); in patients who also affected with diabetes mellitus type 2 (3.2 ± 0.8 ng mL) and patients who also affected with hypertension (4.1 ± 1.2 ng mL) when compared with patients who do not have other diseases (5.7 ± 1.5 ng mL). A negative significant correlation between serum adropin level and BMI (r=0.493; p=0.0001), LDL (r=-0.628; p=0.0001) level and TC (r=-0.249, p=0.018) level. A positive significant (r=0.395, P=0.0001) appeared correlation of adropin level with HDL level. It was observed that a lower adropin level could play a vital role in cardiac pathophysiology and atherosclerosis. Also, a decrease in the adropin level can be considered a risk factor for these patients. Therefore, measurement and surveillance of changes in serum adropin can consider as a new diagnosis and assessment of disease progression.